Ernexa Therapeutics (ERNAW) Long-Term Investments (2021 - 2023)

Ernexa Therapeutics (ERNAW) has 3 years of Long-Term Investments data on file, last reported at $8000.0 in Q1 2023.

• Quarterly Long-Term Investments fell 97.92% year-over-year to $8000.0 in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $8000.0 (down 97.92% YoY) and the FY2022 annual result came in at $59000.0, down 94.1% from the prior year.
• Long-Term Investments eased to $8000.0 in Q1 2023, from $59000.0 in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $1.0 million in Q3 2021 to a low of $8000.0 in Q1 2023.
• A 3-year average of $372714.3 and a median of $89000.0 in 2022 frame the typical range for Long-Term Investments.
• Annual changes were most pronounced in 2022 — Long-Term Investments sank 93.2% — and 2023, when it tumbled 97.92%.
• Tracing ERNAW's Long-Term Investments over 3 years: stood at $1.0 million in 2021, then plunged by 94.1% to $59000.0 in 2022, then slumped by 86.44% to $8000.0 in 2023.
• The last three Long-Term Investments figures came in at $8000.0 (Q1 2023), $59000.0 (Q4 2022), and $68000.0 (Q3 2022), per Business Quant data.